Crescent Biopharma (CBIO) Interest Expenses (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Interest Expenses of $53.0 million for Q1 2026, up 4666.1% year-over-year from $1.1 million in Q1 2025, and up 257.74% quarter-over-quarter from $14.8 million in Q3 2025.
Crescent Biopharma (CBIO) Interest Expenses (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Interest Expenses for 14 consecutive years, with $53.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 4666.1% year-over-year to $53.0 million; the TTM figure through Jun 2026 stood at $2.2 million (down 31.92% YoY), while the FY2025 annual figure was $14.7 million, up 273.48% from the prior year.
- Interest Expenses improved to $53.0 million in Q1 2026 per CBIO's latest filing, from $14.8 million in the prior quarter.
- Across five years, Interest Expenses topped out at $53.0 million in Q1 2026 and bottomed at $172438.0 in Q4 2023.
- Historically, Interest Expenses has averaged $5.0 million across 5 years, with a median of $658075.0 in 2023.
- On a YoY basis, Interest Expenses climbed as much as 5435.4% in 2025 and fell as far as 72.39% in 2025.
- Crescent Biopharma's Interest Expenses stood at $279692.0 in 2022, then plunged by 38.35% to $172438.0 in 2023, then soared by 394.09% to $852000.0 in 2024, then surged by 1638.85% to $14.8 million in 2025, then surged by 257.74% to $53.0 million in 2026.
- Business Quant data shows CBIO's Interest Expenses at $53.0 million in Q1 2026, $14.8 million in Q3 2025, and $1.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.00 Mn |
| Mar 31, 2026 | 53.00 Mn |
| Jun 30, 2025 | 30.59 Mn |
| Jun 30, 2025 | 30.59 Mn |
| Mar 31, 2025 | 1.11 Mn |
| Mar 31, 2025 | 1.11 Mn |
| Dec 31, 2024 | 852,000.00 |
| Dec 31, 2024 | 852,000.00 |
| Sep 30, 2024 | 5,508.00 |
| Sep 30, 2024 | 5,508.00 |
| Jun 30, 2024 | 463,956.00 |
| Jun 30, 2024 | 463,956.00 |
| Mar 31, 2024 | 4.03 Mn |
| Mar 31, 2024 | 4.03 Mn |
| Dec 31, 2023 | 172,438.00 |
| Dec 31, 2023 | 172,438.00 |
| Sep 30, 2023 | 655,000.00 |
| Sep 30, 2023 | 655,000.00 |
| Jun 30, 2023 | 1.04 Mn |
| Jun 30, 2023 | 1.04 Mn |